Provided by Tiger Trade Technology Pte. Ltd.

Bristol-Myers Squibb

63.73
-0.3700-0.58%
Post-market: 63.61-0.1200-0.19%19:43 EDT
Volume:10.00M
Turnover:636.90M
Market Cap:129.74B
PE:14.03
High:64.13
Open:63.94
Low:63.15
Close:64.10
52wk High:68.64
52wk Low:42.52
Shares:2.04B
Float Shares:2.03B
Volume Ratio:1.37
T/O Rate:0.49%
Dividend:2.51
Dividend Rate:3.94%
EPS(TTM):4.54
EPS(LYR):3.46
ROE:46.60%
ROA:10.72%
PB:5.81
PE(LYR):18.42

Loading ...

Bristol Myers Sues Amgen over Proposed Opdivo Biosimilar

Reuters
·
9 hours ago

RBC Capital Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)

TIPRANKS
·
Yesterday

BioMarin Appoints Bristol Myers Squibb Research Chief Robert Plenge to Board

Reuters
·
Sep 14

Press Release: BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors

Dow Jones
·
Sep 14

Big Pharma is Pouring Billions into China's Biotechs

Dow Jones
·
Sep 14

Snowflake, Applied Materials, Dell, Zoom, Bristol-Myers Insider Shock

TIPRANKS
·
Sep 12

Top Bristol-Myers Squibb Executive Makes Major Move With Insider Stock Sale

TIPRANKS
·
Sep 11

RBC Capital Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)

TIPRANKS
·
Sep 11

Bristol Myers’ EVP, Chief Medical Officer Cristian Massacesi Disposes of 6,249 Common Shares Worth $403,700.93

Reuters
·
Sep 11

Champions Oncology Q1 Revenue Rises on Research Services Business

Reuters
·
Sep 11

Revolution Medicines Got a 'Miracle' Cancer Drug Approval. Wall Street Wants More.

Dow Jones
·
Sep 11

BMY Targets Pediatric MS Edge With New Ozanimod Study Against Fingolimod

TIPRANKS
·
Sep 11

Bristol-Myers Squibb’s Long-Term Psoriasis Study Brings Fresh Data for BMY Investors

TIPRANKS
·
Sep 11

Bladder Cancer Trial Completion Puts Opdivo in Focus for BMY and Ono Investors

TIPRANKS
·
Sep 11

Cytokinetics Has Advantage in Bristol-Myers Squibb Patent Dispute, RBC Says

MT Newswires Live
·
Sep 11

Bristol-Myers Squibb is Maintained at Hold by HSBC

Dow Jones
·
Sep 10

Bloomsbury Executives Adjust Holdings After 2023 Share Plan Vesting

TIPRANKS
·
Sep 10

HSBC Adjusts Price Target on Bristol-Myers Squibb to $65 From $60, Keeps Hold Rating

MT Newswires Live
·
Sep 10

Scotiabank Keeps Their Hold Rating on Bristol-Myers Squibb (BMY)

TIPRANKS
·
Sep 09

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bristol-Myers Squibb (BMY), Stryker (SYK) and InnovAge Holding (INNV)

TIPRANKS
·
Sep 09